<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03564704</url>
  </required_header>
  <id_info>
    <org_study_id>PDT-ALL-LBL</org_study_id>
    <nct_id>NCT03564704</nct_id>
  </id_info>
  <brief_title>Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL</brief_title>
  <official_title>An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016
      protocol, this open-label, one-arm, multi-site trial PDT-ALL-LBL is aimed to evaluate the
      safety and effect of oral histone deacetylase inhibitor chidamide for adult T-ALL/LBL.
      Compared to PDT-ALL-2016 for B-ALL, HDACi chidamide will be administrated from induction
      therapy to maintenance therapy, along with higher dose of consolidation regimen of
      cytarabine, methotrexate, cyclophosphamide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      T-lymphoblastic lymphoma/leukemia is a neoplasm of lymphoblasts committed to the T-cell
      lineage, typically composed of small to medium-sized blast with scant cytoplasm, moderately
      condensed to dispersed chromatin, and inconspicuous nucleoli, involving bone marrow and blood
      or presenting with primary involvement of the thymus or of nodal or extranodal sites.
      T-ALL/LBL is generally considered a higher-risk disease than B-ALL. Compared to B-ALL,
      T-LBL/ALL is associated with a higher risk of induction failure, early relapse, and isolated
      CNS relapse.

      Chidamide is a novel oral HDACi with promising activity in non-Hodgkin lymphoma (NHL).
      Chidamide, a new oral isotype-selective HDACi, approved in China for the treatment of R/R
      PTCL in December 2014. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and
      MRD-directed PDT-ALL-2016 protocol, this open-label, two-arm, multi-site trial PDT-ALL-LBL is
      aimed to evaluate the safety and effect of oral histone deacetylase inhibitor chidamide for
      adult T-ALL/LBL. Compared to PDT-ALL-2016 for B-ALL, HDACi chidamide will be administrated
      from induction therapy to maintenance therapy, along with higher dose of consolidation
      regimen of cytarabine, methotrexate, cyclophosphamide.

      The intervention of PDT-ALL-LBL consists of diagnostic test (bone marrow aspiration, flow
      immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (chidamide,
      dexamethasone, vincristine, cyclophosphamide, Idarubicin, pegaspargase), consolidation
      regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide,
      adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment (MRD1/d14, MRD2/d24, MRD3/d45,
      MRD4/pre-allo-HSCT) and maintenance regimen (chidamide, vincristine, methotrexate,
      6-mercaptopurine), intrathecal injection, radiation therapy (for mediastinum- and/or central
      nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell
      transplantation for patients with donor.

      Induction Regimen-Pretreatment: dexamethasone, -3d to 0d; Induction regimen VICLD: VCR: d1,
      d8, d15, d22; IDA: d1, d8; CTX: 1g/m2, 1; PEG-asp: 2000-2500IU/m2, 1, 15; dexamethasone:
      1-24; chidamide: 10mg/d, po, qd. Flow-based MRD assessment: d14, d24 during induction
      regimen, d45, and pre-HSCT. Salvage regimen VLCAM (MRD1/d24&gt;1%): CTX, d25; AraC 50mg/m2,
      d25-31; 6-MP: 25-31, PEG-asp: 2500IU/m2, d26. Consolidation Module (CM)-CM1: AraC 3g/m2,
      q12h, d1-2, Dex: 10mg/m2, d1-2, PEG-asp: 2, 6-MP: d1-7, chidamide, po qd; CM2: MTX 5g/m2, 1,
      Dex: 10mg/m2, 1-2, PEG-asp: d2, 6-MP: 1-7, chidamide, po qd; CM3: CTX 1g/m2, 1-3, PEG-asp: 2,
      6-MP: 1-7, chidamide, po qd. CM4-6: repeat CM 1-3. Re-Induction: VICLD after CM6. CM7-9:
      repeat CM1-3. Allo-HSCT: after CM3 when matched-related-donor (MRD), haploidentical related
      donor (HRD) or matched-unrelated-donor (MUD) available. Non-allo-HSCT: finish CM4-9 and CPOMP
      maintenance. Maintenance Module-CPOMP: chidamide, po qd for 24 months; Pred: for 12 months;
      VCR for 12 months; MTX: for 24m months; 6-MP for 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2016</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-Free-Survival</measure>
    <time_frame>3 years</time_frame>
    <description>3 years EFS of LBL/ALL patients enrolled in PDT-ALL-LBL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimum residual disease after induction</measure>
    <time_frame>3 months</time_frame>
    <description>MRD after induction regimen of PDT-ALL-LBL protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR after Induction Therapy</measure>
    <time_frame>3 months</time_frame>
    <description>CR after induction regimen of PDT-ALL-LBL protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death in induction</measure>
    <time_frame>3 months</time_frame>
    <description>Dearth during induction regimen of PDT-ALL-LBL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>AE of 3 years of LBL patients enrolled in PDT-ALL-LBL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>3 years</time_frame>
    <description>Cumulative incidence relapse rate of 3 years of LBL patients enrolled in PDT-ALL-LBL protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>3 years</time_frame>
    <description>3 years RFS of LBL patients enrolled in PDT-ALL-LBL protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>3 years OS of LBL patients enrolled in PDT-ALL-LBL protocol</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Leukemia</condition>
  <condition>Leukemia, Acute</condition>
  <condition>Adult Lymphoblastic Lymphoma</condition>
  <condition>Leukemia, Lymphoblastic</condition>
  <condition>Leukemia, T Cell</condition>
  <condition>Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Lymphoblastic Lymphoma</condition>
  <condition>Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention of PDT-ALL-LBL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy (methotrexate, cytarabine, dexamethasone), radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <other_name>DXM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine</intervention_name>
    <description>Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <other_name>VCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <other_name>IDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <other_name>PEG-ASP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
    <description>Adriamycin will be added to Consolidation-Module of PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <other_name>ADR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate will be added to Consolidation-Module of PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-mercaptopurine.</intervention_name>
    <description>Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <other_name>6-MP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>VP-16 will be added to Consolidation-Module of PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <other_name>VP-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>AraC will be added to Consolidation-Module of PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <other_name>AraC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow aspiration</intervention_name>
    <description>Bone marrow aspiration and additional tests will be performed in all module of PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <other_name>BM smear</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intrathecal injection</intervention_name>
    <description>Intrathecal injection of chemotherapy will be performed in PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <other_name>IT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>Radiation therapy will be performed for mediastinum and/or central nervous system leukemia/lymphoma in PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <other_name>RT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>NGS</intervention_name>
    <description>Next-Generation-Sequencing (NGS) will be performed in PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Allo-HSCT will be added to LBL patients with available donor in PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <other_name>Allo-HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Flow-MRD</intervention_name>
    <description>Flow-MRD will be added to PDT-ALL-LBL for bone marrow and cerebrospinal fluid samples.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FISH</intervention_name>
    <description>FISH will be added to PDT-ALL-LBL for bone marrow samples.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Flow immunophenotyping</intervention_name>
    <description>Flow immunophenotyping will be performed in PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Karyotyping</intervention_name>
    <description>Karyotyping will be performed in PDT-ALL-LBL protocol.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>HDACi chidamide will be added to induction regimen, consolidation and maintenance module of PDT-ALL-LBL.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <other_name>HDACi Chidamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET-CT scan</intervention_name>
    <description>PET-scan will be performed for T-LBL patients for MRD assessment in PDT-ALL-LBL.</description>
    <arm_group_label>PDT-ALL-LBL</arm_group_label>
    <other_name>PET-CT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  14-55 years old;

          -  LBL/ALL newly diagnosed;

          -  signed written informed consent.

        Exclusion Criteria:

          -  Pregnant women;

          -  History of pancreatitis;

          -  History of diabetes;

          -  History of active peptic ulcer disease in the past 6 months;

          -  History of arteriovenous thrombosis in the past 6 months;

          -  Severe active infection;

          -  Allergic to any drugs in PDT-ALL-LBL protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifa Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Hematology Nanfang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongsheng Zhou</last_name>
    <phone>+862062787349</phone>
    <email>zhs1@i.smu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology, Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongsheng Zhou</last_name>
      <phone>+862062787349</phone>
      <email>zhs1@i.smu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>June 11, 2018</last_update_submitted>
  <last_update_submitted_qc>June 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Qifa Liu</investigator_full_name>
    <investigator_title>M.D., Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

